Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 2

Classical, Micropulse and NanoSecond Laser Therapy in Dry-Form (Non-Neovascular) Age Related Macular Degeneration

Kuru Tip (Non-Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Klasik, Mikropulse ve Nano Saniye Lazer Tedavisi

Pages
155–159
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Antioxidants, visual cycle inhibitors, anti-inflammatory agents, neuroprotective treatment, conventional, micropulse and nano-second laser applications are intended to regulate the various mechanisms involved in the pathogenesis of the disease

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Age related macular degeneration (AMD), which is a multifactorial, degenerative disease of retina, is the most common reason of legal blindness over 50 years of age.
📊
Key Findings & Data:Epidemiological, histopathological and biochemical data demonstrate that AMD is associated with oxidative damage, lipofuscin accumulation, chronic inflammation, and mutations in the complement system.
💡
Conclusion & Impact:Antioxidants, visual cycle inhibitors, anti-inflammatory agents, neuroprotective treatment, conventional, micropulse and nano-second laser applications are intended to regulate the various mechanisms involved in the pathogenesis of the disease
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Age related macular degeneration (AMD), which is a multifactorial, degenerative disease of retina, is the most common reason of legal blindness over 50 years of age. Dry-form (non neovascular) AMD is the common type, and frequently non progressive to total vision loss. Epidemiological, histopathological and biochemical data demonstrate that AMD is associated with oxidative damage, lipofuscin accumulation, chronic inflammation, and mutations in the complement system. Drusen, hyperpigmentation/hypopigmentation in retinal pigment epithelium, and geographical atrophy can also be observed in dry-form AMD. Various treatment modalities can be used according to the stages of the disease. Antioxidants, visual cycle inhibitors, anti-inflammatory agents, neuroprotective treatment, conventional, micropulse and nano-second laser applications are intended to regulate the various mechanisms involved in the pathogenesis of the disease

Özet

Yaşa bağlı maküla dejenerasyonu (YBMD), 50 yaşın üzerinde bireylerde geri dönüşümsüz görme kaybının en sık nedeni olan, multifaktöriyel ve dejeneratif bir retina hastalığıdır. Kuru tip (non-neovasküler) YBMD, daha sık görülen, yavaş gelişen ve çoğunlukla total görme kaybına ilerlemeyen tipidir. Epidemiyolojik, histopatolojik ve biyokimyasal veriler YBMD'nin oksidatif hasar, lipofusin birikimi, kronik inflamasyon ve kompleman sisteminde meydana gelen mutasyonlar ile ilişkili olduğunu göstermektedir. Druzen, retina pigment epitelinde hiperpigmentasyon/hipopigmentasyon ve coğrafik atrofi kuru tip YBMD de gözlenebilmektedir. Hastalığın evresine göre farklı tedavi çeşitleri bulunmaktadır. Antioksidanlar, vizüel siklus inhibitörleri, anti-inflamatuvar ajanlar, nöroprotektif tedavi, konvansiyonel, mikropulse ve nano-saniye lazer uygulamaları hastalığın patogenezinde bulunan çeşitli mekanizmaları düzenlemeye yöneliktir

🔖

Cite This Article

BİÇER, T., ÇITIRIK, M. (2017). Classical, Micropulse and NanoSecond Laser Therapy in Dry-Form (Non-Neovascular) Age Related Macular Degeneration. Güncel Retina Dergisi, Cilt: 1 - Sayı: 2, 155–159. https://ajindex.com/articles/197476

References (16)

  1. Bressler NM, Bressler SB, Congdon NG, Ferris FL, Friedman DS, Klein R,et al. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no
  2. Arch Ophthalmol. 2003;121(11):1621–24
  3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol.1984;102(11):1640-42
  4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355(14):1419–31
  5. Gillies MC, Walton R, Simpson JM, Arnold JJ, Guymer RH, McAllister IL, et al. Fight Retinal Blindness! Project Investigators. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. Invest. Ophthalmol. Vis. Sci. 2013;54(8):5754–60
  6. Holz FG, Wolfensberger TJ, Piguet B, Gross-Jendroska M, Wells JA, Minassian DC, et al. Bilateral macular drusen in age-related macular degeneration. Prognosis and risk factors. Ophthalmology. 1994;101(9):522-28
  7. Gren WR, Key SN: Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc. 1977;75:180-254
  8. Gren WR, McDonnell PH, Yeo JH. Pathologic features of senile macular degeneration. Ophthalmology. 1985;92(5):615-27
  9. Bressler NM, Bressler SB, Seddon JM, Gragoudas ES, Jacobson LP. Drusen characteristics in patients with exudative versus non-exudative age-related macular degeneration. Retina. 1998;8(2):109-14
  10. Sramek CK, Leung L-S, Paulus YM, Palanker DV. Therapeutic window of retinal photocoagulation with green (532-nm) and yellow (577-nm) lasers. Ophthalmic Surg. Lasers Imaging. 2012;43(4):341–47
  11. Gass JDM. Drusen and disciform macular detachment and degeneration. Arch Ophthalmol. 1973;90(3):206-17
  12. Cleasby GW, Nakanishi AS, Norris JL. Propylactic photocoagulation of the fellow eye in exudative senile maculopathy. A preliminary report. Mod Probl Ophthalmol. 1979;20:141-47
  13. Figueroa MS, Regueras A, Bertrand J. Laser photocoagulation to treat macular soft drusen in age-related macular degeneration. Retina. 1994;14(5):391-96
  14. Figueroa MS, Regueras A, Bertrand J, Aparicio MJ, Manrique MG. Laser photocoagulation for macular soft drusen. Updated results. Retina. 1997;17(5):378-84
  15. Little HL, Showman JM, Brown BW. A pilot randomized controlled study on the effect of laser photocoagulation of confluent soft macular drusen. Ophthalmology. 1997;104(4):623-31
  16. Choroidal Neovascul